Showing results (191-200 of 447) with videos related to
Sort By:
Pageof 45
Journal of Cancer Research and Clinical Oncology|July 28, 2022
Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patientsRyoko Inaba Higashiyama, Hidehito Horinouchi, Aya Kuchiba, et al.Cancer Science|September 11, 2019
Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancerYoshinori Makino, Reiko Makihara-Ando, Takanori Ogawa, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 3, 2011
Risk factors for treatment-related death associated with chemotherapy and thoracic radiotherapy for lung cancerYuko Minami-Shimmyo, Yuichiro Ohe, Seiichiro Yamamoto, et al.Japanese Journal of Clinical Oncology|March 11, 2026
Socioeconomic and financial factors associated with financial toxicity in Japanese cancer patients: a cross-sectional studyKazuki Yokoyama, Kazunori Honda, Kazuko Matsumoto, et al.Japanese Journal of Clinical Oncology|September 28, 2010
Lung cancer working group reportNagahiro Saijo, Masahiro Fukuoka, Sumitra Thongprasert, et al.Respiration; International Review of Thoracic Diseases|December 21, 2022
Feasibility of Modified Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy: A Retrospective AnalysisAya Konno-Yamamoto, Yuji Matsumoto, Tatsuya Imabayashi, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 27, 2009
Relation between elective nodal failure and irradiated volume in non-small-cell lung cancer (NSCLC) treated with radiotherapy using conventional fields and dosesNaoko Sanuki-Fujimoto, Minako Sumi, Yoshinori Ito, et al.Lung Cancer (Amsterdam, Netherlands)|September 2, 2015
Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutationsEri Sugiyama, Shigeki Umemura, Shogo Nomura, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2008
EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in JapanToshimi Takano, Tomoya Fukui, Yuichiro Ohe, et al.Journal of Cancer Research and Clinical Oncology|August 27, 2013
Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinomaTatsuya Yoshida, Genichiro Ishii, Koichi Goto, et al.Pageof 45